TMS for Anxiety: Evidence, Protocols, and What to Expect

TMS for anxiety exists in an interesting space: widely used off-label, backed by a growing body of clinical evidence, but not yet FDA-cleared for any anxiety disorder specifically. If you have been researching TMS as a treatment option for anxiety, this gap between clinical practice and regulatory status can be confusing. Here is where things actually stand, what the evidence shows, and what you should know before pursuing this option.

The short version: TMS shows real promise for anxiety, particularly when anxiety co-occurs with depression (which is the majority of cases). Several specific protocols are being studied, and off-label use is growing rapidly. But the evidence is not yet at the level that led to FDA clearance for depression, and the optimal protocol for anxiety as a primary condition is still being defined.

The Anxiety-Depression Overlap

Before diving into TMS for anxiety specifically, it is worth understanding why anxiety and depression are so intertwined in the TMS conversation.

Roughly 60% of people with major depression also have clinically significant anxiety. And many people with primary anxiety disorders develop depression over time. The two conditions share overlapping brain circuits, particularly involving the prefrontal cortex, amygdala, and anterior cingulate cortex (1).

This overlap has a practical consequence for TMS: many patients who undergo TMS for FDA-cleared depression also experience substantial improvement in their anxiety symptoms. In the large NeuroStar naturalistic registry (over 5,000 patients), anxiety severity decreased significantly alongside depression improvement in patients receiving standard left DLPFC TMS (2).

This means that if you have both depression and anxiety, getting TMS for depression (which is FDA-cleared and covered by most insurance plans) may address both conditions. This is the most straightforward path to accessing TMS for anxiety-related symptoms today.

Why Right vs. Left DLPFC Matters for Anxiety

TMS for depression targets the left dorsolateral prefrontal cortex (DLPFC) with high-frequency (excitatory) stimulation, based on evidence that this region is underactive in depression. For anxiety, the picture is more complex and points in a different direction.

The valence model of prefrontal function suggests that the left DLPFC is more involved in positive approach behaviors and the right DLPFC is more involved in avoidance and threat monitoring. In anxiety, the right DLPFC may be relatively overactive, contributing to excessive threat detection, worry, and avoidance behavior (3).

This has led researchers to test two anxiety-specific TMS approaches:

• Low-frequency (inhibitory) stimulation of the right DLPFC: The goal is to reduce overactivity in the right prefrontal region, dampening excessive anxiety processing. Studies using 1 Hz rTMS to the right DLPFC have shown significant anxiety reduction (4)
• High-frequency stimulation of the left DLPFC: The standard depression protocol may reduce anxiety indirectly by strengthening the left prefrontal cortex’s ability to regulate emotions and override anxious rumination (5)

Some clinicians now use bilateral protocols: high-frequency stimulation to the left DLPFC followed by low-frequency stimulation to the right DLPFC in the same session. Early evidence suggests this combined approach may be particularly effective for patients with both depression and anxiety (6).

The Evidence by Anxiety Subtype

Anxiety is not one condition. Generalized anxiety disorder, social anxiety, panic disorder, and PTSD-related anxiety involve overlapping but distinct brain circuits. The TMS evidence varies by subtype.

Generalized Anxiety Disorder (GAD)

GAD is characterized by chronic, excessive worry about multiple life domains. Several studies have examined TMS for GAD specifically:

• A 2019 randomized controlled trial of right DLPFC low-frequency rTMS in 40 GAD patients found significant improvement in anxiety scores compared to sham, with effects maintained at 4-week follow-up (7)
• A meta-analysis of TMS for GAD found a moderate to large effect size favoring active TMS over sham, though the number of high-quality trials remains small (8)
• Bilateral protocols (combining left excitatory and right inhibitory stimulation) have shown promising results in open-label studies for GAD

Social Anxiety Disorder

Research on TMS for social anxiety is earlier stage but intriguing. Social anxiety involves overactivation of threat-processing circuits, particularly the amygdala and its connections to the prefrontal cortex. TMS targeting the right DLPFC may help regulate these circuits, and a small number of studies have shown symptom improvement. This area needs more research before firm conclusions can be drawn.

PTSD-Related Anxiety

PTSD involves a distinct pattern of brain dysfunction, with an overactive amygdala and underactive prefrontal cortex failing to regulate fear responses. TMS for PTSD has been studied more extensively than for other anxiety subtypes:

• Both right low-frequency and left high-frequency protocols have shown benefits for PTSD symptoms
• A 2020 meta-analysis found that TMS produced significant improvement in PTSD symptoms compared to sham treatment (9)
• The VA (Veterans Affairs) system has been a major driver of PTSD-related TMS research and clinical adoption

Panic Disorder

Evidence for TMS in panic disorder is limited to small studies and case series. While some patients report reduced panic frequency and severity, the data is insufficient to draw strong conclusions. Panic disorder is typically well-managed with SSRIs and cognitive-behavioral therapy, so TMS research has focused on more treatment-resistant anxiety presentations.

Intermittent Theta Burst Stimulation (iTBS) for Anxiety

iTBS is a newer TMS protocol that delivers stimulation in a pattern mimicking the brain’s natural theta rhythm. Each session takes only about 3 minutes (compared to 19 to 37 minutes for standard rTMS), making it dramatically more practical. iTBS received FDA clearance for depression in 2018 and is the basis for the accelerated SAINT protocol.

For anxiety, iTBS is generating significant research interest:

• The shorter session time makes it possible to deliver multiple sessions per day, enabling accelerated treatment courses
• Preliminary studies suggest iTBS to the right DLPFC may be effective for anxiety, with some evidence of equivalent or superior efficacy compared to standard rTMS (10)
• The efficiency of iTBS means that bilateral protocols (stimulating both left and right DLPFC) become more practical within a single appointment

iTBS is still being optimized for anxiety specifically. Watch for upcoming trial results that may clarify the best iTBS parameters for different anxiety subtypes.

TMS for Anxiety vs. Medication

SSRIs remain the first-line pharmacological treatment for most anxiety disorders. They work for many people, have decades of safety data, and are inexpensive. TMS becomes most relevant when SSRIs have not worked, when their side effects are intolerable, or when patients want to avoid long-term medication use.

Benzodiazepines deserve special mention because they are still widely prescribed for anxiety despite serious concerns about dependence, cognitive impairment, and fall risk. For patients currently on benzodiazepines who want to taper off, TMS may provide an alternative source of symptom control during the withdrawal process, though this application has not been studied systematically.

What Response Rates Look Like

Across published studies, response rates for TMS in anxiety range from about 40% to 70%, depending on the specific anxiety condition, the TMS protocol used, and how response is defined. A few benchmarks:

• Comorbid anxiety during depression TMS: roughly 50 to 60% show significant anxiety improvement alongside depression response
• GAD-specific protocols: approximately 50 to 65% response in published trials
• PTSD: approximately 40 to 60% response, with some studies showing higher rates with extended protocols

These numbers are encouraging but come with caveats. Most anxiety-specific TMS studies are small (under 100 participants), and the heterogeneity of protocols makes comparison difficult. Larger, well-controlled trials are needed before definitive response rates can be established.

Cost and Insurance Considerations

Here is the practical reality of paying for TMS when anxiety is the primary condition:

If you have comorbid depression: This is the most straightforward path. TMS is FDA-cleared for treatment-resistant depression, and most insurance plans cover it after failed antidepressant trials. Since anxiety and depression so commonly co-occur, many patients can honestly qualify for TMS coverage through their depression diagnosis, and the anxiety improvement comes along with it.

If anxiety is your primary condition without significant depression: Coverage becomes more challenging. Some providers can justify TMS based on off-label use protocols and clinical necessity, but approval rates are lower and appeals may be required. Out-of-pocket costs for a full course run $6,000 to $15,000, consistent with TMS for depression.

Finding a TMS Provider for Anxiety

Not all TMS providers have experience treating anxiety as a primary target. When searching for a provider, consider:

• Experience with anxiety protocols: Ask whether they offer right DLPFC or bilateral stimulation, not just the standard left DLPFC depression protocol
• Protocol flexibility: A good provider should evaluate your specific presentation and adjust the protocol accordingly, rather than offering a one-size-fits-all approach
• Psychiatric expertise: The treating psychiatrist should understand the nuances of anxiety subtypes and be able to distinguish between anxiety that will respond to standard depression TMS and anxiety that needs a modified protocol
• Outcome tracking: Look for providers who use standardized anxiety measures (like the GAD-7 or Hamilton Anxiety Rating Scale) to track your progress throughout treatment
• iTBS availability: Providers offering iTBS protocols have access to the newest stimulation patterns being studied for anxiety

What to Expect During Treatment

The treatment experience for TMS anxiety protocols is very similar to TMS for depression. You sit in a comfortable chair while a magnetic coil is positioned against your head. You remain fully awake. The session lasts 3 to 37 minutes depending on the protocol (iTBS is shorter, standard rTMS is longer). You may hear clicking sounds and feel a tapping sensation. After the session, you leave and resume normal activities immediately.

If a bilateral protocol is used, you may have two coil positions during the same session: one on the left side and one on the right. This extends the appointment time but is still typically under an hour total.

A standard course involves 5 sessions per week for 4 to 6 weeks. Some providers are exploring accelerated protocols (multiple sessions per day over a shorter period), similar to the SAINT protocol used for depression, though this is still investigational for anxiety.

Most patients notice gradual changes: less intensity of worry, longer periods of calm between anxious episodes, easier time engaging in previously avoided situations. The improvement tends to build progressively over the treatment course rather than appearing suddenly.

The Bottom Line

TMS for anxiety is a treatment in evolution. The evidence is real and growing, but it has not yet reached the threshold that led to FDA clearance for depression. For patients with comorbid depression and anxiety, TMS is already a strong option with excellent insurance coverage. For patients with primary anxiety without depression, TMS is a reasonable off-label option to explore after first-line treatments (SSRIs, CBT, or both) have not provided adequate relief.

The next few years will likely bring clearer answers. Multiple large trials are underway testing anxiety-specific TMS protocols, and FDA clearance for one or more anxiety indications is plausible within the next several years. In the meantime, the off-label evidence is strong enough that TMS deserves consideration as part of a treatment-resistant anxiety management strategy, particularly if you can find a provider with specific experience in anxiety-focused protocols.

References

1. Gorman JM. (1996). Comorbid depression and anxiety spectrum disorders. Depression and Anxiety, 4(4), 160-168. doi:10.1002/(SICI)1520-6394(1996)4:4<160::AID-DA2>3.0.CO;2-J
2. Carpenter LL, et al. (2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety, 29(7), 587-596. doi:10.1002/da.21969
3. Grimm S, et al. (2008). Imbalance between left and right dorsolateral prefrontal cortex in major depression is linked to negative emotional judgment: an fMRI study in severe major depressive disorder. Biological Psychiatry, 63(4), 369-376. doi:10.1016/j.biopsych.2007.05.033
4. Diefenbach GJ, et al. (2016). Repetitive transcranial magnetic stimulation for generalised anxiety disorder: a pilot randomised, double-blind, sham-controlled trial. British Journal of Psychiatry, 209(3), 222-228. doi:10.1192/bjp.bp.115.168203
5. Chen L, et al. (2019). High-frequency left-sided rTMS reduces anxiety symptoms in a real-world sample. Brain Stimulation, 12(2), 496-497. doi:10.1016/j.brs.2018.12.600
6. Berlim MT, Van den Eynde F. (2014). Repetitive transcranial magnetic stimulation over the dorsolateral prefrontal cortex for treating posttraumatic stress disorder: an exploratory meta-analysis of randomized, double-blind and sham-controlled trials. Canadian Journal of Psychiatry, 59(9), 487-496. doi:10.1177/070674371405900907
7. Dilkov D, et al. (2017). Repetitive transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in the treatment of generalized anxiety disorder: a randomized, double-blind sham controlled clinical trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 78, 61-65. doi:10.1016/j.pnpbp.2017.05.018
8. Cirillo P, et al. (2019). Transcranial magnetic stimulation in anxiety and trauma-related disorders: a systematic review and meta-analysis. Brain and Behavior, 9(6), e01284. doi:10.1002/brb3.1284
9. Kan RLD, et al. (2020). Non-invasive brain stimulation for posttraumatic stress disorder: a systematic review and meta-analysis. Translational Psychiatry, 10, 168. doi:10.1038/s41398-020-0851-5
10. Bulteau S, et al. (2022). Intermittent theta burst stimulation for anxiety disorders: a systematic review. Brain Stimulation, 15(3), 773-781. doi:10.1016/j.brs.2022.04.016

Related Reading

• Complete Guide to TMS Therapy
• Ketamine for Anxiety: Does It Work and What to Expect
• TMS for Depression: Treating Treatment-Resistant Depression
• Biofeedback for Anxiety: How It Works and Where to Start
• TMS for OCD: Deep Brain Stimulation Without Surgery